National Institute for Health and Care Excellence

Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

This guidance updates and replaces NICE's technology appraisal guidance 212 on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment ...
National Institute for Health and Care Excellence

Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy is available on the NHS. It is a possible first- or second-line treatment for metastatic colorectal cancer in adults, ...
ascopubs.org

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
Hosted on MSN

Better survival in refractory CRC with chemo plus bevacizumab, real-world study says

Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF inhibitor bevacizumab (Avastin) to chemotherapy, data from a real-world ...